zolpidem (SL800750)

DRUG2 trials

Sponsors

Sanofi

Conditions

Attention Deficit Hyperactivity DisorderSleep Initiation and Maintenance Disorders

Phase 3

Efficacy, Safety, and Tolerability of Ambien (Zolpidem) in the Treatment of Children Ages 6 to 17 With Attention Deficit Hyperactivity Disorder (ADHD)-Associated Insomnia

CompletedNCT00318448

SanofiAttention Deficit Hyperactivity Disorder

Start: 2006-04-30End: 2006-08-31Updated: 2009-04-07

Evaluation of the Hypnotic Properties of Zolpidem-MR 12.5 mg and Zolpidem 10 mg Marketed Product Compared to Placebo in Patients With Primary Insomnia

CompletedNCT00630175

SanofiSleep Initiation and Maintenance Disorders

Start: 2003-09-30End: 2004-02-29Updated: 2009-05-18